Werewolf Therapeutics, Inc. Share Price
NASDAQ: HOWL | Micro CapWerewolf Therapeutics, Inc. Stock Performance
Open $0.41 | Prev. Close $0.40 | Circuit Range N/A |
Day Range $0.40 - $0.42 | Year Range $0.28 - $2.35 | Volume 3,100 |
Average Traded $0.41 |
Werewolf Therapeutics, Inc. Share Price Today
As of 10 August 2026, Werewolf Therapeutics, Inc.'s share price is $0.40. The stock opened at $0.41, compared to its previous close of $0.40. During today's trading session, Werewolf Therapeutics, Inc.'s share price traded between $0.40 and $0.42, with an average price of $0.41. Over the past 52 weeks, the stock has recorded a high of $2.35 and a low of $0.28. In terms of performance, Werewolf Therapeutics, Inc.'s share price has declined by 34.00% over the last six months and is down 69.85% on a year-on-year basis.
Werewolf Therapeutics, Inc. Share Price Chart
Werewolf Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $18.32M | PE Ratio (TTM) -0.30 | Dividend Yield N/A |
EPS (TTM) $-1.32 | Revenue (TTM) N/A | Return On Equity (TTM) -245.20% |
Profit Margin N/A | Debt to Equity 1.46 | Quarterly Earnings Growth YoY 1.82% |
Werewolf Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Werewolf Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Werewolf Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $0.37 | $0.40 | +12.75% |
Jul 2026 | $0.36 | $0.35 | -1.12% |
Jun 2026 | $0.46 | $0.36 | -20.67% |
May 2026 | $0.74 | $0.45 | -39.27% |
Apr 2026 | $0.87 | $0.74 | -12.31% |
Mar 2026 | $0.57 | $0.84 | +40.13% |
Feb 2026 | $0.68 | $0.60 | -12.48% |
Jan 2026 | $0.63 | $0.69 | +9.37% |
Dec 2025 | $0.97 | $0.63 | -37.62% |
Nov 2025 | $1.32 | $1.01 | -22.61% |
Oct 2025 | $2.01 | $1.30 | -33.42% |
Sep 2025 | $1.31 | $1.96 | +48.48% |
HOWL Share Price FAQs
What is Werewolf Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Werewolf Therapeutics, Inc. stock?
What is HOWL's market capitalisation today?
What is HOWL's net income for the last quarter?
What is the 5 year returns of HOWL?
What is the high & low stock price of HOWL today?
Can I buy HOWL shares in India?